Last reviewed · How we verify
NCT04191941
Treatment of Hematological Malignancy With Novel CAR-T Cells.
EARLY_PHASE1 trial testing Novel CAR-T in B-cell Non Hodgkin Lymphoma in 9 participants. Status unknown.
31 August 2021
Quick facts
| Lead sponsor | Timmune Biotech Inc. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 1 September 2019 |
| Primary completion | 31 August 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Novel CAR-T — full drug profile →
Conditions studied
- B-cell Non Hodgkin Lymphoma — all drugs for B-cell Non Hodgkin Lymphoma →
- B-cell Acute Lymphoblastic Leukemia — all drugs for B-cell Acute Lymphoblastic Leukemia →
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Timmune Biotech Inc. — full company profile →
Who can join
Under 70, any sex, with B-cell Non Hodgkin Lymphoma or B-cell Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2 -
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Yin Z, Zhang Y, Wang X. · · 2021 · cited 30× · PMID 34256851 · DOI 10.1186/s40364-021-00309-5 -
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT, Ye JC. · · 2021 · cited 21× · PMID 34301270 · DOI 10.1186/s13045-021-01109-y
Verify or expand the search:
- PubMed search for NCT04191941
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B-cell Non Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06707259 — Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL · Phase 1 · recruiting
- NCT06392477 — A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgki · Phase 1 · recruiting
- NCT06508775 — Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies · NA · recruiting
- NCT05991388 — A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma · Phase 2, PHASE3 · recruiting
- NCT05702853 — Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL · Phase 1, PHASE2 · recruiting
Other Timmune Biotech Inc. trials
Trials by the same sponsor.
- NCT03910842 — Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy · EARLY_PHASE1 · unknown
- NCT03790891 — Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy · EARLY_PHASE1 · unknown
- NCT03720496 — Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy · Phase 1 · unknown
- NCT03649529 — Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy · EARLY_PHASE1 · unknown
- NCT03497533 — Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04191941 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Timmune Biotech Inc.
- Last refreshed: 10 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04191941.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing